Your browser doesn't support javascript.
loading
Optimization and scale-up production of Zika virus ΔNS1 in Escherichia coli: application of Response Surface Methodology.
Kanno, Alex Issamu; Leite, Luciana Cezar de Cerqueira; Pereira, Lennon Ramos; de Jesus, Mônica Josiane Rodrigues; Andreata-Santos, Robert; Alves, Rúbens Prince Dos Santos; Durigon, Edison Luiz; Ferreira, Luís Carlos de Souza; Gonçalves, Viviane Maimoni.
Afiliação
  • Kanno AI; Laboratório de Desenvolvimento de Vacinas, Instituto Butantan, Av Vital Brasil, 1500, São Paulo, SP, 05503-900, Brazil.
  • Leite LCC; Laboratório de Desenvolvimento de Vacinas, Instituto Butantan, Av Vital Brasil, 1500, São Paulo, SP, 05503-900, Brazil.
  • Pereira LR; Laboratório de Desenvolvimento de Vacinas, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, SP, Brazil.
  • de Jesus MJR; Laboratório de Desenvolvimento de Vacinas, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, SP, Brazil.
  • Andreata-Santos R; Laboratório de Desenvolvimento de Vacinas, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, SP, Brazil.
  • Alves RPDS; Laboratório de Desenvolvimento de Vacinas, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, SP, Brazil.
  • Durigon EL; Laboratório de Virologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, SP, Brazil.
  • Ferreira LCS; Laboratório de Desenvolvimento de Vacinas, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, SP, Brazil.
  • Gonçalves VM; Laboratório de Desenvolvimento de Vacinas, Instituto Butantan, Av Vital Brasil, 1500, São Paulo, SP, 05503-900, Brazil. viviane.goncalves@butantan.gov.br.
AMB Express ; 10(1): 1, 2019 Dec 31.
Article em En | MEDLINE | ID: mdl-31893321
Diagnosing Zika virus (ZIKV) infections has been challenging due to the cross-reactivity of induced antibodies with other flavivirus. The concomitant occurrence of ZIKV and Dengue virus (DENV) in endemic regions requires diagnostic tools with the ability to distinguish these two viral infections. Recent studies demonstrated that immunoassays using the C-terminal fragment of ZIKV NS1 antigen (ΔNS1) can be used to discriminate ZIKV from DENV infections. In order to be used in serological tests, the expression/solubility of ΔNS1 and growth of recombinant E. coli strain were optimized by Response Surface Methodology. Temperature, time and IPTG concentration were evaluated. According to the model, the best condition determined in small scale cultures was 21 °C for 20 h with 0.7 mM of IPTG, which predicted 7.5 g/L of biomass and 962 mg/L of ΔNS1. These conditions were validated and used in a 6-L batch in the bioreactor, which produced 6.4 g/L of biomass and 500 mg/L of ΔNS1 in 12 h of induction. The serological ELISA test performed with purified ΔNS1 showed low cross-reactivity with antibodies from DENV-infected human subjects. Denaturation of ΔNS1 decreased the detection of anti-ZIKV antibodies, thus indicating the contribution of conformational epitopes and confirming the importance of properly folded ΔNS1 for the specificity of the serological analyses. Obtaining high yields of soluble ΔNS1 supports the viability of an effective serologic diagnostic test capable of differentiating ZIKV from other flavivirus infections.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2019 Tipo de documento: Article